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BACKGROUND

No therapies for targeting KRAS mutations in cancer have been approved. The
KRAS p.G12C mutation occurs in 13% of non–small-cell lung cancers (NSCLCs)
and in 1 to 3% of colorectal cancers and other cancers. Sotorasib is a small molecule that selectively and irreversibly targets KRASG12C.
METHODS

We conducted a phase 1 trial of sotorasib in patients with advanced solid tumors
harboring the KRAS p.G12C mutation. Patients received sotorasib orally once
daily. The primary end point was safety. Key secondary end points were pharmacokinetics and objective response, as assessed according to Response Evaluation
Criteria in Solid Tumors (RECIST), version 1.1.
RESULTS

A total of 129 patients (59 with NSCLC, 42 with colorectal cancer, and 28 with
other tumors) were included in dose escalation and expansion cohorts. Patients
had received a median of 3 (range, 0 to 11) previous lines of anticancer therapies
for metastatic disease. No dose-limiting toxic effects or treatment-related deaths
were observed. A total of 73 patients (56.6%) had treatment-related adverse events;
15 patients (11.6%) had grade 3 or 4 events. In the subgroup with NSCLC, 32.2%
(19 patients) had a confirmed objective response (complete or partial response)
and 88.1% (52 patients) had disease control (objective response or stable disease);
the median progression-free survival was 6.3 months (range, 0.0+ to 14.9 [with +
indicating that the value includes patient data that were censored at data cutoff]).
In the subgroup with colorectal cancer, 7.1% (3 patients) had a confirmed response, and 73.8% (31 patients) had disease control; the median progression-free
survival was 4.0 months (range, 0.0+ to 11.1+). Responses were also observed in
patients with pancreatic, endometrial, and appendiceal cancers and melanoma.
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CONCLUSIONS

Sotorasib showed encouraging anticancer activity in patients with heavily pretreated advanced solid tumors harboring the KRAS p.G12C mutation. Grade 3 or 4
treatment-related toxic effects occurred in 11.6% of the patients. (Funded by Amgen and others; CodeBreaK100 ClinicalTrials.gov number, NCT03600883.)
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irsten rat sarcoma viral oncogene
homologue (KRAS) is the most frequently
mutated oncogene in human cancers and
encodes a guanosine triphosphatase (GTPase)
that cycles between active guanosine triphosphate
(GTP)–bound and inactive guanosine diphosphate
(GDP)–bound states to regulate signal transduction.1 KRAS mutations are often associated with
resistance to targeted therapies and poor outcomes in patients with cancer, yet no selective
KRAS inhibitor has been approved despite more
than three decades of scientific effort.2-12
The KRAS p.G12C mutation occurs in approximately 13% of non–small-cell lung cancers
(NSCLCs) and in 1 to 3% of colorectal cancers
and other solid cancers.8,13-15 The glycine-to-cysteine mutation at position 12 favors the active
form of the KRAS protein, resulting in a predominantly GTP-bound KRAS oncoprotein and
enhanced proliferation and survival in tumor
cells.16,17 The mutated cysteine resides next to a
pocket (P2) of the switch II region. The P2
pocket is present only in the inactive GDP-bound
conformation of KRAS and has been exploited
to establish covalent inhibitors of KRASG12C.16,18,19
Sotorasib (AMG 510) is a small molecule that
specifically and irreversibly inhibits KRASG12C
through a unique interaction with the P2 pocket
(Fig. S1 in the Supplementary Appendix, available
with the full text of this article at NEJM.org).20
The inhibitor traps KRASG12C in the inactive
GDP-bound state by a mechanism similar to that
described for other KRASG12C inhibitors.18 Preclinical studies showed that sotorasib inhibited
nearly all detectable phosphorylation of extracellular signal-regulated kinase (ERK), a key downstream effector of KRAS, leading to durable
complete tumor regression in mice bearing
KRAS p.G12C tumors.20
In this phase 1 trial, we evaluated the safety,
pharmacokinetics, and efficacy of sotorasib in
patients with advanced solid tumors harboring
the KRAS p.G12C mutation.

Me thods
Eligibility criteria included an age of 18 years or
older; histologically confirmed, locally advanced
or metastatic cancer with the KRAS p.G12C mutation identified by local molecular testing on
tumor tissues; an Eastern Cooperative Oncology
Group (ECOG) performance status of 0 to 2 (on
n engl j med 383;13
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a 5-point scale, with higher numbers indicating
greater disability); measurable disease according
to Response Evaluation Criteria in Solid Tumors
(RECIST), version 1.1; for patients with NSCLC,
previous platinum-based combination therapy,
targeted therapies, or both; for patients with
colorectal cancer, at least two previous lines of
systemic therapy for metastatic disease (patients
who have colorectal cancer characterized by
high microsatellite instability must have received
at least nivolumab or pembrolizumab if clinically applicable); and for patients with solid tumors other than NSCLC or colorectal cancer, at
least one previous line of systemic therapy.
Key exclusion criteria were untreated active
brain metastases, systemic antitumor therapy
within 28 days before initiation of sotorasib
therapy, and radiation therapy within 2 weeks
before initiation of sotorasib therapy. Full eligibility and exclusion criteria are provided in the
protocol, available at NEJM.org.
Trial Design

We conducted a phase 1, multicenter, open-label
trial of sotorasib in patients with advanced solid
tumors harboring the KRAS p.G12C mutation.
The trial consisted of dose escalation and expansion cohorts. Sotorasib was administered orally
once daily. The planned dose levels for the escalation cohorts (1 through 4) were 180, 360, 720,
and 960 mg, with two to four patients receiving
treatment in each cohort. Each treatment cycle
was 21 days. Administration of sotorasib continued until occurrence of progressive disease,
development of unacceptable side effects, withdrawal of consent, or end of study. A two-parameter Bayesian logistics-regression model was used
to guide dose escalation. Intrapatient dose escalations were permitted for cohorts 1 through 3,
and additional patients could be enrolled to a
particular cohort once a dose for that cohort was
deemed safe. The expansion cohort opened once
the recommended phase 2 dose had been determined.
Study Oversight

Patients

1208

of

The protocol and amendments were approved by
the institutional review board or ethics committee at each participating site. The trial was conducted in accordance with the International
Council for Harmonisation Good Clinical Practice guidelines and the principles of the Declaration of Helsinki. All patients provided written
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informed consent. The study was designed by
employees of Amgen (the main sponsor) in collaboration with the investigators. The data were
collected by investigators and were analyzed by
statisticians employed by Amgen. A medical
writer employed by Amgen provided the first
draft of the manuscript and editorial assistance.
All authors contributed to interpretation of the
data and preparation of the manuscript and
vouch for the completeness and accuracy of the
data and the fidelity of the trial to the protocol.
End Points

The primary end point was safety, including the
incidence of dose-limiting toxic effects (defined
as sotorasib-related toxic effects within the first
21 days after the first dose), adverse events during the treatment period, and treatment-related
adverse events. Adverse events were graded with
the use of the Common Terminology Criteria for
Adverse Events (CTCAE), version 5.0.
Secondary end points included the following
pharmacokinetic variables: the maximum plasma concentration, the time to achieve maximum
plasma concentration, and the area under the
plasma concentration-time curve. Additional secondary end points, measured by computed tomography (CT) or magnetic resonance imaging and
assessed by independent radiologic review according to RECIST 1.1, were objective response (complete or partial response), duration of response,
disease control (objective response or stable disease at the week 6 assessment, with imaging performed within 1 week before or 1 week after the
assessment), progression-free survival, and duration of stable disease. Response data included in
this article were evaluated by local investigators.
Statistical Analysis

This analysis included all patients enrolled in the
cohorts that received monotherapy once daily
(dose escalation and expansion cohorts). The
date of data cutoff was June 1, 2020.
A maximum enrollment of 92 patients was
planned for the dose escalation cohorts, and the
outcomes in approximately 30 patients were
analyzed to estimate the recommended phase 2
dose. Once the phase 2 dose was determined,
the dose expansion cohort was opened to enroll
approximately 20 to 60 patients. We calculated
that with 60 patients in the expansion cohort,
there would be a 45 to 95% probability of observing at least one adverse event if the true
n engl j med 383;13

event rate was 1 to 5%. After a minimum of 20
patients were treated at the recommended phase
2 dose and at least 10 of these patients had at
least one assessment of tumor response, the doselevel review team reviewed all available safety,
laboratory, pharmacokinetic, and efficacy data to
make a recommendation to proceed to phase 2.

R e sult s
Trial Population

A total of 129 patients, including 59 with NSCLC,
42 with colorectal cancer, and 28 with other
tumor types, were enrolled in dose escalation
and expansion cohorts (Fig. S2). This analysis
was conducted in the full phase 1 population
that received daily monotherapy with sotorasib.
The median follow-up was 11.7 months (range,
4.6 to 21.2). Treatment was discontinued in 107
patients (82.9%); the most common reason for
discontinuation was disease progression. As of
the data cutoff date of June 1, 2020, 54 patients
(41.9%) had died. The median duration of treatment was 3.9 months (range, 0 to 16.6). A total of
74 patients (57.4%) received treatment for 3 months
or more, and 38 (29.5%) for 6 months or more.
Baseline characteristics are summarized in
Table 1 (with additional details in Table S1). The
median age was 62 years (range, 33 to 83). Most
of the enrolled patients were heavily pretreated,
with a median of 3 (range, 0 to 11) previous
lines of anticancer therapy for metastatic disease; 78 patients (60.5%) had received 3 or more
previous lines, and 75% of patients with NSCLC
and 98% with colorectal cancer had received 2 or
more previous lines of therapy. Of the 59 patients
with NSCLC, 53 (89.8%) were current or former
smokers, 53 (89.8%) had received anti–programmed cell death protein 1 (PD-1) or anti–programmed death ligand 1 (PD-L1) therapies, and
all (100%) had received platinum-based chemotherapy.
Safety

No dose-limiting toxic effects were observed. No
treatment-related adverse events resulted in death.
Adverse events of any cause that occurred during
treatment were reported in 125 patients (96.9%)
(Table 2). The most common events were diarrhea (in 38 patients [29.5%]), fatigue (in 30
[23.3%]), and nausea (in 27 [20.9%]). Adverse
events of grade 3 or higher that occurred during
treatment were reported in 68 patients (52.7%).
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Table 1. Patient Characteristics at Baseline.*
Cohort 1
180 mg
(N = 6)

Characteristics
Median age (range) — yr
Female sex — no. (%)

60 (54–75)

Cohort 2
360 mg
(N = 27)

Cohort 3
720 mg
(N = 11)

60 (33–78)

67 (40–76)

Cohort 4
960 mg
(N = 85)

All Patients
(N = 129)

64 (37–83)

62 (33–83)

3 (50.0)

20 (74.1)

6 (54.5)

37 (43.5)

66 (51.2)

White

6 (100.0)

22 (81.5)

9 (81.8)

61 (71.8)

98 (76.0)

Asian

0

1 (3.7)

15 (17.6)

16 (12.4)

Black

0

1 (3.7)

1 (9.1)

4 (4.7)

6 (4.7)

Other

0

3 (11.1)

1 (9.1)

5 (5.9)

9 (7.0)

Race — no. (%)†
0

Primary tumor type
NSCLC — no. (%)

3 (50.0)

16 (59.3)

6 (54.5)

34 (40.0)

59 (45.7)

15/16 (93.8)

5/6 (83.3)

30/34 (88.2)

53/59 (89.8)

2/3 (66.7)

11/16 (68.8)

4/6 (66.7)

18/34 (52.9)

35/59 (59.3)

3/3 (100.0)

16/16 (100.0)

6/6 (100.0)

28/34 (82.4)

53/59 (89.8)

3/3 (100.0)

16/16 (100.0)

6/6 (100.0)

34/34 (100.0)

59/59 (100.0)

Current or former smoker — no./total
no. (%)

3/3 (100.0)

Female sex — no./total no. (%)
Previous anti–PD-1 or anti–PD-L1 ther
apies — no./total no. (%)
Previous platinum-based chemotherapy
— no./total no. (%)
Colorectal cancer — no. (%)

3 (50.0)

10 (37.0)

4 (36.4)

25 (29.4)

42 (32.6)

0

1 (3.7)

1 (9.1)

26 (30.6)

28 (21.7)

0

2 (33.3)

6 (22.2)

1 (9.1)

26 (30.6)

35 (27.1)

1

3 (50.0)

21 (77.8)

9 (81.8)

54 (63.5)

87 (67.4)

2

1 (16.7)

0

1 (9.1)

5 (5.9)

7 (5.4)

0

1 (3.7)

1 (9.1)

15 (17.6)

17 (13.2)

Other — no. (%)
ECOG performance status — no. (%)‡

Previous anticancer systemic therapy for meta
static disease — no. (%)§
1
2

2 (33.3)

5 (18.5)

1 (9.1)

24 (28.2)

32 (24.8)

3

2 (33.3)

4 (14.8)

4 (36.4)

15 (17.6)

25 (19.4)

>3

2 (33.3)

No. of previous anticancer systemic therapies for
metastatic diseases — median (range)

3.0 (2.0–5.0)

17 (63.0)

5 (45.5)

4.0 (1.0–6.0)

3.0 (1.0–11.0)

29 (34.1)

53 (41.1)

3.0 (0–10.0)

3.0 (0–11.0)

*	Percentages may not total 100 because of rounding. NSCLC denotes non–small-cell lung cancer, PD-1 programmed cell death protein 1,
and PD-L1 programmed death ligand 1.
†	Race was determined by trial investigators.
‡	Eastern Cooperative Oncology Group (ECOG) performance status is measured on a 5-point scale, with higher numbers indicating greater
disability.
§	Adjuvant therapy could be counted if relapse occurred less than 6 months after completion of the therapy.

A total of 73 patients (56.6%) had treatmentrelated adverse events of any grade; 2 patients
(1.6%) had serious adverse events. A total of 15
patients (11.6%) reported grade 3 or 4 treatmentrelated adverse events. Grade 3 treatment-related
adverse events included an increase in the alanine aminotransferase (ALT) level (in 4.7% of the
patients), diarrhea (in 3.9%), anemia (in 3.1%),
an increase in the aspartate aminotransferase
1210

n engl j med 383;13

(AST) level (in 2.3%), an increase in the blood
alkaline phosphatase level (in 1.6%), hepatitis
(in 0.8%), a decrease in lymphocyte count (in
0.8%), an increase in the gamma-glutamyltransferase level (in 0.8%), and hyponatremia (in 0.8%).
One patient (0.8%) reported a grade 4 treatmentrelated elevation of ALT, which returned to the
baseline level after reduction in the dose of sotorasib and tapering of glucocorticoids, and 1 patient
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Table 2. Adverse Events in All 129 Patients.
Events

Any Grade

Grade ≥3

Grade ≥4

Grade 5: Fatal

number (percent)
Adverse events of any cause that occurred during
treatment
Any

125 (96.9)

68 (52.7)

26 (20.2)

22 (17.1)

58 (45.0)

51 (39.5)

25 (19.4)

22 (17.1)

9 (7.0)

9 (7.0)

4 (3.1)

4 (3.1)

Diarrhea

38 (29.5)

5 (3.9)

0

0

Fatigue

30 (23.3)

3 (2.3)

0

0

Nausea

27 (20.9)

2 (1.6)

0

0

Vomiting

23 (17.8)

5 (3.9)

0

0

Abdominal pain

23 (17.8)

4 (3.1)

0

0

Dyspnea

21 (16.3)

3 (2.3)

1 (0.8)

1 (0.8)

Cough

20 (15.5)

0

0

0

Back pain

19 (14.7)

2 (1.6)

0

0

Decreased appetite

19 (14.7)

1 (0.8)

0

0

Headache

18 (14.0)

0

0

0

Aspartate aminotransferase increase

17 (13.2)

3 (2.3)

0

0

Anemia

17 (13.2)

6 (4.7)

0

0

Dizziness

17 (13.2)

0

0

0

Alanine aminotransferase increase

15 (11.6)

6 (4.7)

1 (0.8)

0

Constipation

15 (11.6)

0

0

0

Pyrexia

14 (10.9)

0

0

0

Insomnia

14 (10.9)

0

0

0

Myalgia

13 (10.1)

0

0

0

Peripheral edema

13 (10.1)

0

0

0

Arthralgia

13 (10.1)

2 (1.6)

0

0

Serious
Resulting in discontinuation of treatment*
Adverse events of any cause that occurred during
treatment in ≥10% of patients

*	Among the 22 patients who had fatal adverse events of any cause during treatment, 4 patients discontinued treatment direct
ly because of those adverse events. The remaining patients discontinued treatment before the fatal adverse event occurred,
and therefore the fatal adverse event was not recorded as the reason for treatment discontinuation for those patients.

(0.8%) discontinued treatment because of grade 3
treatment-related increases in ALT and AST levels. (Full lists of adverse events are provided in
Tables S2 and S3.)

variation, 81.7%). The mean (±SD) elimination
half-life was 5.5±1.8 hours. The dose of 960 mg
administered daily was identified as the dose for
the expansion cohort.

Pharmacokinetics

Efficacy

The pharmacokinetic profile of sotorasib administered at a dose of 960 mg daily is shown in
Figure S3. The maximum plasma concentration
was 7.50 μg per milliliter (coefficient of variation, 98.3%), with a median time to maximum
plasma concentration of 2.0 hours (range, 0.3 to
6.0). The 24-hour area under the curve was 65.3
hours × micrograms per milliliter (coefficient of

NSCLC

n engl j med 383;13

The median follow-up time in the subgroup with
NSCLC was 11.7 months (range, 4.8 to 21.2). Of
59 patients with NSCLC, 19 had a confirmed
partial response, and 33 had stable disease; thus,
32.2% of the patients (95% confidence interval
[CI], 20.62 to 45.64) had a confirmed response,
and 88.1% (95% CI, 77.07 to 95.09) had disease
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Table 3. Efficacy of Sotorasib in All Tumor Types.
NSCLC
(N = 59)

Colorectal Cancer
(N = 42)

Other
(N = 28)

0

0

0

Best overall response — no. (%)
Confirmed complete response
Confirmed partial response

19 (32.2)

3 (7.1)

4 (14.3)

Stable disease

33 (55.9)

28 (66.7)

17 (60.7)

Progressive disease

5 (8.5)

10 (23.8)

4 (14.3)

Could not be evaluated

1 (1.7)

0

1 (3.6)

1 (1.7)

1 (2.4)

2 (7.1)

Objective response — % (95% CI)†

No assessment*

32.2 (20.62–45.64)

7.1 (1.50–19.48)

14.3 (4.03–32.67)

Disease control — % (95% CI)‡

88.1 (77.07–95.09)

73.8 (57.96–86.14)

75.0 (55.13–89.31)

*	One patient with NSCLC withdrew consent before tumor assessment. One patient with colorectal cancer and 2 patients
with other tumor types had clinical progression.
†	Objective response was defined as a complete or partial response.
‡	Disease control was defined as a complete response, a partial response, or stable disease.

control (Table 3 and Fig. 1A). Among the 34
patients in the 960-mg cohort, 35.3% (12 patients) had a confirmed response and 91.2% (31
patients) had disease control.
Responses were seen across all dose levels.
One patient with a partial response had a nearcomplete response, with 100% reduction in the
target lesions but persistent nontarget lesions
(Fig. 1A). CT images of patients with NSCLC are
shown in Figure 1B and Figure S4.
Tumor shrinkage of any magnitude was observed in 42 patients (71.2%) at the first assessment, performed at week 6. The median time to
response was 1.4 months (range, 1.1 to 9.5). The
median duration of response was 10.9 months
(range, 1.1+ to 13.6, with + indicating that the
value includes patient data that were censored at
data cutoff); in 10 of the 19 patients with a response, the response was ongoing as of the data
Figure 1 (facing page). Change from Baseline in Tumor
Burden in Patients with NSCLC Receiving Sotorasib.
Panel A shows the best percent change from baseline
in tumor burden (defined by the sum of the longest
diameters of all target lesions) in 57 of 59 patients with
NSCLC for whom postbaseline tumor data were avail
able. PD denotes progressive disease, PR partial response,
and SD stable disease. Panel B shows computed tomo
graphic scans of two target lesions from a 55-year-old
female patient with NSCLC, at baseline and after 10 and
16 weeks of treatment with sotorasib. The patient had a
partial response. Scans and the tumor measurements
are from independent central radiologic review.

n engl j med 383;13

cutoff date (Fig. 2A and 2B). Among patients who
had a response, the duration of response was at
least 3 months in 11 patients (57.9%), at least
6 months in 6 patients (31.6%), and at least
9 months in 5 patients (26.3%). The median duration of stable disease was 4.0 months (range, 1.4
to 10.9+). As of the data cutoff date, 14 patients
(23.7%) were continuing treatment (Fig. 2A). The
median progression-free survival for all patients
with NSCLC was 6.3 months (range, 0.0+ to 14.9)
(Fig. 2C).
Colorectal Cancer

The median follow-up time in the subgroup with
colorectal cancer was 12.8 months (range, 9.0 to
20.9). A confirmed partial response was observed
in 3 of 42 patients (7.1%) with colorectal cancer,
with one response ongoing as of the date of data
cutoff (Table 3 and Fig. S5). The three responses
lasted for 4.9, 6.9, and 9.9+ months, respectively.
A total of 28 patients (66.7%) had stable disease;
thus, 73.8% of the 42 patients had disease control. The median duration of stable disease was
5.4 months (range, 2.5+ to 11.1+). Among the 25
patients in the cohort that received 960 mg daily,
12.0% (3 patients) had a confirmed objective
response and 80.0% (20 patients) had disease
control. Three patients, including 1 patient with
an objective response, were continuing treatment
as of the data cutoff date. The median progression-free survival for all patients with colorectal
cancer was 4.0 months (range, 0.0+ to 11.1+).
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Patients with NSCLC Receiving Sotorasib

A Time to Response, Disease Progression, and Treatment Duration

First response
Death
Progression
Treatment
ongoing

Planned Dose
180 mg
360 mg
720 mg
960 mg
0

1

2

3

4

5

6
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Figure 2 (facing page). Efficacy of Sotorasib in Patients
with NSCLC.
Panel A shows the time to response, the duration of
treatment, and patient status by the data cutoff date
for all 59 patients with NSCLC, according to the dose
of sotorasib. Panel B shows the change in tumor bur
den over time in 57 of 59 patients with NSCLC for whom
postbaseline tumor data were available. Panel C shows
a Kaplan–Meier curve of progression-free survival for
all 59 patients with NSCLC.

Other Tumor Types

Among patients with other tumor types, 4 had a
confirmed partial response (1 with pancreatic
cancer, 1 with endometrial cancer, 1 with appendiceal cancer, and 1 with melanoma), 17 had
stable disease, and 4 had progressive disease.
The four responses lasted for 4.4, 6.9+, 2.7, and
5.6 months, respectively. Five patients were continuing treatment as of the data cutoff date
(Table 3 and Fig. S6).

Discussion
Since its discovery in 1982, the mutated KRAS
protein has been deemed “undruggable” owing
to its high affinity for GTP and lack of accessible
binding pockets, as well as toxic effects associated with other KRAS-targeting approaches.21,22
However, the discovery by Ostrem et al. of compounds that covalently bind to the switch II
pocket of KRASG12C established the foundation
for the development of inhibitors suitable for
clinical testing.16 Subsequently, Lito et al. and
Patricelli et al. established the mechanism of
KRASG12C inhibition (i.e., trapping the oncoprotein in its inactive state by blocking reactivation
through nucleotide exchange).18,19 Sotorasib inhibits KRASG12C by a similar mechanism, but its
potency and selectivity were enhanced through
the optimization of novel interactions with a
previously unexploited surface groove.20 The
KRASG12C inhibitor sotorasib has the potential to
address the unmet need for treatment of tumors
harboring the KRAS p.G12C mutation.16,18 Here,
we evaluated the safety and clinical activity associated with sotorasib in this full phase 1 cohort
receiving daily monotherapy. Results showed that
a KRASG12C inhibitor produced durable clinical
benefit with mainly low-grade gastrointestinal
and hepatic toxic effects in a heavily pretreated
population.
n engl j med 383;13

Despite the fact that the cancers in our patient population had been refractory to previous
treatments, 32.2% of the patients with NSCLC
had a confirmed response, and the majority
(88.1%) had disease control for a few months or
more with sotorasib, leading to a median progression-free survival of 6.3 months. Similarly,
most patients in the colorectal cancer subgroup
had disease control, with a median duration of
stable disease of 5.4 months and median progression-free survival of 4.0 months. With current therapies, approximately 9 to 18% of patients
with NSCLC have a response to second- or thirdline therapies, with median progression-free survival of 2.5 to 4.0 months,23,24 and approximately
1.0 to 1.6% of patients with previously treated
colorectal cancer have a response to standard
therapies, with median progression-free survival
of 1.9 to 2.1 months.25-27 Thus, the treatment outcome in patients with NSCLC or colorectal cancer similar to patients in our study is generally
poor. Responses and disease stability associated
with sotorasib in these patients are encouraging.
In the NSCLC subgroup, the fact that 32.2%
of the patients across all dose levels and 35.3%
at the target dose of 960 mg had a response was
particularly promising. Rapid responses to sotorasib were seen at the first assessment, performed
at week 6, and responses were durable and ongoing at a median follow-up of nearly a year. Nine
of the 19 patients who had a partial response, as
well as 5 patients who had stable disease, were
still receiving treatment as of the data cutoff date.
The median duration of response among all patients who had a response was 10.9 months.
Nevertheless, some patients had disease progression shortly after an initial response. Twentyfour patients (40.7%) had at least one assessment
of partial response according to RECIST 1.1
criteria, and 19 (32.2%) had a confirmed partial
response. Of the 5 patients who had a partial
response that was never confirmed, 1 had longterm stable disease, whereas 4 had rapid disease
progression (2 in target lesions and 2 in nontarget lesions). Rapid progression might suggest a
high degree of tumor heterogeneity in these patients with late-stage disease or an early adaptation to treatment, as reported in a preclinical study
with a precursor inhibitor.28 The molecular signature of the tumors from patient subgroups with
distinct response patterns awaits further investigation.
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The inconsistency in tumor response between
NSCLC and colorectal cancer suggests either that
KRAS p.G12C is not the dominant oncogenic
driver for colorectal cancer or that other pathways, such as Wnt or EGFR pathways, mediate
oncogenic signaling beyond KRAS, a hypothesis
supported by recently published preclinical evidence.28-30 Therefore, combining sotorasib with
therapies that block additional pathways may be
a viable option, as shown by studies in BRAF
V600E–mutant colorectal cancer.31-33 Patients who
have colorectal cancer with RAS mutations do not
benefit from standard anti-EGFR combination
therapies.34 These patients have poorer progression-free survival and overall survival than those
with wild-type KRAS.35,36 Considering the poor
prognosis in patients with metastatic disease and
the lack of effective treatments in this population, controlling the tumor burden with an oral
therapy for a few months may be meaningful.
Sotorasib is a covalent inhibitor that rapidly
occupies KRASG12C and extinguishes its activity.
The turnover rate of KRASG12C is relatively slow
(with a half-life of approximately 22 hours).20
Therefore, a relatively brief exposure to sotorasib
at concentrations sufficient to completely occupy
the existing pool of KRASG12C would be predicted
to completely inhibit the protein for approximately 24 hours. In a finding consistent with
this hypothesis, in multiple KRAS p.G12C in vivo
tumor models, plasma exposures to sotorasib
above the 90% maximal inhibitory concentration (IC90) of the cellular ERK phosphorylation
assay for 4 hours resulted in maximum suppression of ERK phosphorylation for at least 24 hours
and maximum tumor regression.20 The observed
mean exposure to sotorasib at a dose of 960 mg
markedly exceeds this same threshold for approximately 24 hours and is therefore predicted

of

m e dic i n e

to achieve near total occupancy and inhibition of
KRASG12C over the entire dosing interval. The
response with a daily dose of 960 mg appeared
to be higher than that across all doses combined. The 960-mg daily dose was advanced to
later confirmatory trials.
To date, no dose-limiting toxic effects have
been observed with sotorasib, even with extended
treatment. The majority of patients had some
toxic effects, although they were mainly of lowgrade. Diarrhea, nausea, vomiting, fatigue, and
elevations of aminotransferase levels were the
most common adverse events, but few patients
stopped treatment because of toxic effects.
We found that sotorasib showed promising
anticancer activity in patients with heavily pretreated KRAS p.G12C mutant solid tumors. Trials
evaluating sotorasib as monotherapy or in combination with various agents in patients with
NSCLC or other solid tumors are under way
(ClinicalTrials.gov numbers, NCT04303780 and
NCT04185883).
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